Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 11Colorectal Neoplasms 4Breast Neoplasms 3Solid Tumors 2Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Glioblastoma 1Gallbladder Neoplasms 1Disease Progression 1Disease 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Blood Specimen Collection 6Prednisone 5Positron Emission Tomography Computed Tomography 4Mammography 4Lenalidomide 4Colonoscopy 4pembrolizumab 3Tomography, X-Ray Computed 3Surveys and Questionnaires 3Melphalan 3Exercise 3Biopsy 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Preoperative Exercise 2Positron-Emission Tomography 2Methods 2Magnetic Resonance Imaging 2Injections 2Gemcitabine 2Educational Status 2Doxorubicin 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease × tivozanib × Clear all
NCT01728181 2013-07-25

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

University of Utah

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡